2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
1998
Prader-Willi Syndrome
Martin A, State M, Koenig K, Schultz R, Dykens EM, Cassidy SB, Leckman JF. Prader-Willi Syndrome. American Journal Of Psychiatry 1998, 155: 1265-1273. PMID: 9734553, DOI: 10.1176/ajp.155.9.1265.Peer-Reviewed Original Research
1995
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases. The Journal Of Clinical Psychiatry 1995, 56: 526-8. PMID: 7592506.Peer-Reviewed Original ResearchConceptsSerotonin uptake inhibitorObsessive-compulsive disorderYale-Brown Obsessive Compulsive ScaleY-BOCS scoresRisperidone additionOCD patientsComorbid chronic tic disorderPatients' Y-BOCS scoresRefractory obsessive-compulsive disorderOpen-label mannerLow-dose haloperidolSide effect profileWeeks of treatmentChronic tic disorderEffective treatment strategiesObsessive Compulsive ScaleSUI treatmentEffect profileNeuroleptic treatmentTardive dyskinesiaTypical neurolepticsModerate sedationReceptor antagonistTic disordersTreatment strategies
1994
Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics
McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol Addition in Fluvoxamine-Refractory Obsessive-Compulsive Disorder: A Double-blind, Placebo-Controlled Study in Patients With and Without Tics. JAMA Psychiatry 1994, 51: 302-308. PMID: 8161290, DOI: 10.1001/archpsyc.1994.03950040046006.Peer-Reviewed Original ResearchConceptsComorbid chronic tic disorderChronic tic disorderYale-Brown Obsessive Compulsive ScaleObsessive-compulsive disorderTic disordersFluvoxamine treatmentOCD patientsClinical Global Impression ScalePlacebo-treated groupDouble-blind fashionWeeks of treatmentGlobal Impression ScaleTreatment of patientsHaloperidol-treated groupEffective symptom reductionObsessive Compulsive ScaleNeuroleptic therapyBlood levelsImpression ScaleTreatment outcomesTreatment responseAdequate treatmentPatientsPlaceboSymptom reduction
1993
Limited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder
McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz E, Heninger GR, Price LH. Limited therapeutic effect of addition of buspirone in fluvoxamine- refractory obsessive-compulsive disorder. American Journal Of Psychiatry 1993, 150: 647-649. PMID: 8465885, DOI: 10.1176/ajp.150.4.647.Peer-Reviewed Original Research